logo-loader
viewImmuPharma PLC

Share Price Volatility

/**/ sup{font-size:80%}h2{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;font-size:14.0pt;font-family:"Calibri Light","sans-serif";font-weight:bold;font-div:italic;}h4{margin-right:0cm;margin-left:0cm;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .ae{size:595.0pt 842.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ae{}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";}span.bi{font-size:11.0pt;color:#2D2D2D}p.bk{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold}p.bl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.bg{font-size:11.0pt}p.bm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.bd{font-size:11.0pt; color:#2D2D2D}table.bn{margin-left:-10.8pt;border-collapse:collapse} td.an{width:455.3pt;padding:0cm 5.4pt 0cm 5.4pt}p.bo{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:justify; text-autospace:none;vertical-align:baseline}span.bc{font-size:10.0pt; color:black}table.bp{border-collapse:collapse}td.ay{width:294.0pt;padding:0cm 5.4pt 0cm 5.4pt}span.ba{font-size:10.0pt}a.az{font-weight: bold}td.ax{width:194.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.bq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; punctuation-wrap: simple; text-align: justify; text-autospace: none; vertical-align: baseline}span.aw{font-size: 10.0pt} span.au{font-size: 10.0pt;color:black}span.at{font-size:10.0pt;color:black}p.br{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify}span.ar{font-size:10.0pt; color:windowtext;text-decoration:none}p.bs{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-right:-5.4pt;text-align:justify; text-autospace:none;vertical-align:baseline}p.bt{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:justify;text-autospace:none}p.bu{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-autospace:none}p.bv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 15.0pt}span.ak{font-size:10.0pt; color:#2D2D2D}p.bw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-bottom:15.0pt;text-align:justify} span.ai{font-size:10.0pt;color:#2D2D2D}span.ah{color:#2D2D2D}p.bx{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; punctuation-wrap: simple; text-autospace: none; vertical-align: baseline} /**/
RNS Number : 5515W
Immupharma PLC
11 December 2019
 

11 December 2019

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

SHARE PRICE VOLATILITY

 

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that  following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, we note the volatility in the Company's share price and speculation concerning a possible fundraising.  The Board can confirm that the Company is adequately funded and has no intention of raising funds.

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

 

 

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 8974

 

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

 

 

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. For additional information about ImmuPharma please visit www.immupharma.com. 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBDBDDLSBBGCB

Quick facts: ImmuPharma PLC

Price: 13.89

Market: AIM
Market Cap: £23.25 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' ...

The Life Sciences Division's Navid Malik gives his view on the recent recent deal ImmuPharma PLC (LON:IMM) struck with US speciality drugs group Avion Pharmaceuticals. Malik reckons its lupus candidate Lupuzor could become a 'US blockbuster' by generating over US$1bn revenues per year.

on 16/12/19